Form 4: Inovio Pharmaceuticals CEO Jacqueline Shea Acquires Restricted Stock Units and Options
SEC Form 4 Filing
Inovio Pharmaceuticals' CEO, Jacqueline Shea, reports the acquisition of restricted stock units and stock options, signaling potential future ownership in the company.
Summary
- Jacqueline Shea, CEO of Inovio Pharmaceuticals, filed a Form 4 detailing changes in her beneficial ownership of the company's securities.
- On May 20, 2025, Shea acquired 84,888 restricted stock units (RSUs) and 105,262 stock options.
- The RSUs vest in three equal installments of 28,296 shares on May 20, 2026, May 20, 2027, and May 20, 2028.
- Vested RSUs can be settled in shares of common stock, cash, or a combination of both.
- The stock options have an exercise price of $2.13 and vest in two equal installments of 52,631 shares on May 20, 2027, and May 20, 2028, expiring on May 20, 2035.
- Following these transactions, Shea directly owns 84,888 RSUs and 105,262 stock options.
Sentiment
Score: 7
Explanation: The sentiment is moderately positive as the CEO's acquisition of RSUs and options suggests confidence in the company's future, though it's a routine filing.
Positives
- The acquisition of RSUs and stock options by the CEO could be interpreted as a positive sign, indicating confidence in the company's future performance.
- The vesting schedules for both RSUs and options incentivize long-term commitment from the CEO.
Future Outlook
The vesting schedules for the RSUs and stock options suggest a long-term commitment from the CEO to the company's success.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. The acquisition of equity by the CEO is generally viewed positively by investors.
Stakeholder Impact
- The CEO's increased equity stake could align her interests more closely with those of shareholders.
- Employees may view the CEO's acquisition of equity as a positive sign for the company's future.
Key Dates
| Date | Description |
|---|---|
| 05/20/2025 | Date of the transaction: acquisition of RSUs and stock options. |
| 05/20/2026 | First vesting date for 28,296 restricted stock units. |
| 05/20/2027 | Second vesting date for 28,296 restricted stock units and first vesting date for 52,631 stock options. |
| 05/20/2028 | Third vesting date for 28,296 restricted stock units and second vesting date for 52,631 stock options. |
| 05/20/2035 | Expiration date for the 105,262 stock options. |
| 05/21/2025 | Date of signature for the Form 4 filing. |
Keywords
Inovio Pharmaceuticals, Jacqueline Shea, Form 4, Restricted Stock Units, Stock Options, Beneficial Ownership, INO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.